These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 31596553)

  • 1. A Micellar Mitotane Formulation with High Drug-Loading and Solubility: Physico-Chemical Characterization and Cytotoxicity Studies in 2D and 3D In Vitro Tumor Models.
    Haider MS; Schreiner J; Kendl S; Kroiss M; Luxenhofer R
    Macromol Biosci; 2020 Jan; 20(1):e1900178. PubMed ID: 31596553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Challenging Pharmacokinetics of Mitotane: An Old Drug in Need of New Packaging.
    Haider MS; Ahmad T; Groll J; Scherf-Clavel O; Kroiss M; Luxenhofer R
    Eur J Drug Metab Pharmacokinet; 2021 Sep; 46(5):575-593. PubMed ID: 34287806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells.
    Gagliano T; Gentilin E; Benfini K; Di Pasquale C; Tassinari M; Falletta S; Feo C; Tagliati F; Uberti ED; Zatelli MC
    Endocrine; 2014 Dec; 47(3):943-51. PubMed ID: 25096913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells.
    Sbiera S; Leich E; Liebisch G; Sbiera I; Schirbel A; Wiemer L; Matysik S; Eckhardt C; Gardill F; Gehl A; Kendl S; Weigand I; Bala M; Ronchi CL; Deutschbein T; Schmitz G; Rosenwald A; Allolio B; Fassnacht M; Kroiss M
    Endocrinology; 2015 Nov; 156(11):3895-908. PubMed ID: 26305886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitotane liposomes for potential treatment of adrenal cortical carcinoma:
    Zancanella P; Oliveira DML; de Oliveira BH; Woiski TD; Pinto CC; Santana MHA; Souto EB; Severino P
    Pharm Dev Technol; 2020 Oct; 25(8):949-961. PubMed ID: 32343624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of long-lasting effects of mitotane adjuvant therapy in a mouse xenograft model of adrenocortical carcinoma.
    Doghman M; Lalli E
    Mol Cell Endocrinol; 2013 Dec; 381(1-2):66-9. PubMed ID: 23906534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro cytotoxicity of cabazitaxel in adrenocortical carcinoma cell lines and human adrenocortical carcinoma primary cell cultures
    Fragni M; Palma Lopez LP; Rossini E; Abate A; Cosentini D; Salvi V; Vezzoli S; Poliani PL; Bosisio D; Hantel C; Tiberio GAM; Grisanti S; Memo M; Terzolo M; Berruti A; Sigala S
    Mol Cell Endocrinol; 2019 Dec; 498():110585. PubMed ID: 31536779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a pharmacokinetic model of mitotane: toward personalized dosing in adrenocortical carcinoma.
    Kerkhofs TM; Derijks LJ; Ettaieb H; den Hartigh J; Neef K; Gelderblom H; Guchelaar HJ; Haak HR
    Ther Drug Monit; 2015 Feb; 37(1):58-65. PubMed ID: 24887633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma.
    Barlaskar FM; Spalding AC; Heaton JH; Kuick R; Kim AC; Thomas DG; Giordano TJ; Ben-Josef E; Hammer GD
    J Clin Endocrinol Metab; 2009 Jan; 94(1):204-12. PubMed ID: 18854392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potentiation of mitotane action by rosuvastatin: New insights for adrenocortical carcinoma management.
    Boulate G; Amazit L; Naman A; Seck A; Paci A; Lombes A; Pussard E; Baudin E; Lombes M; Hescot S
    Int J Oncol; 2019 Jun; 54(6):2149-2156. PubMed ID: 30942448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma.
    Germano A; Rossin D; Leoni V; Iaia N; Saba L; Basile V; Puglisi S; Caccia C; Poli G; Biasi F; Terzolo M
    Cells; 2020 Apr; 9(4):. PubMed ID: 32260362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro antitumor activity of progesterone in human adrenocortical carcinoma.
    Fragni M; Fiorentini C; Rossini E; Fisogni S; Vezzoli S; Bonini SA; Dalmiglio C; Grisanti S; Tiberio GAM; Claps M; Cosentini D; Salvi V; Bosisio D; Terzolo M; Missale C; Facchetti F; Memo M; Berruti A; Sigala S
    Endocrine; 2019 Mar; 63(3):592-601. PubMed ID: 30367443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipoprotein-Free Mitotane Exerts High Cytotoxic Activity in Adrenocortical Carcinoma.
    Hescot S; Seck A; Guerin M; Cockenpot F; Huby T; Broutin S; Young J; Paci A; Baudin E; Lombès M
    J Clin Endocrinol Metab; 2015 Aug; 100(8):2890-8. PubMed ID: 26120791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting heterogeneity of adrenocortical carcinoma: Evaluation and extension of preclinical tumor models to improve clinical translation.
    Hantel C; Shapiro I; Poli G; Chiapponi C; Bidlingmaier M; Reincke M; Luconi M; Jung S; Beuschlein F
    Oncotarget; 2016 Nov; 7(48):79292-79304. PubMed ID: 27764813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitotane Nanocarriers for the Treatment of Adrenocortical Carcinoma: Evaluation of Albumin-Stabilized Nanoparticles and Liposomes in a Preclinical In Vitro Study with 3D Spheroids.
    Langer C; Köll-Weber M; Holzer M; Hantel C; Süss R
    Pharmaceutics; 2022 Sep; 14(9):. PubMed ID: 36145639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines.
    Cerquetti L; Bucci B; Marchese R; Misiti S; De Paula U; Miceli R; Muleti A; Amendola D; Piergrossi P; Brunetti E; Toscano V; Stigliano A
    Endocr Relat Cancer; 2008 Jun; 15(2):623-34. PubMed ID: 18509009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Human Adrenocortical Cancer Cell Growth by Temozolomide in Vitro and the Role of the MGMT Gene.
    Creemers SG; van Koetsveld PM; van den Dungen ES; Korpershoek E; van Kemenade FJ; Franssen GJ; de Herder WW; Feelders RA; Hofland LJ
    J Clin Endocrinol Metab; 2016 Dec; 101(12):4574-4584. PubMed ID: 27603910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up.
    Mauclère-Denost S; Leboulleux S; Borget I; Paci A; Young J; Al Ghuzlan A; Deandreis D; Drouard L; Tabarin A; Chanson P; Schlumberger M; Baudin E
    Eur J Endocrinol; 2012 Feb; 166(2):261-8. PubMed ID: 22048971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of mitotane lipid nanocarriers and enantiomers: two-in-one solution to efficiently treat adreno-cortical carcinoma.
    Menaa F; Menaa B
    Curr Med Chem; 2012; 19(34):5854-62. PubMed ID: 22934807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ribociclib Cytotoxicity Alone or Combined With Progesterone and/or Mitotane in in Vitro Adrenocortical Carcinoma Cells.
    Abate A; Rossini E; Tamburello M; Laganà M; Cosentini D; Grisanti S; Fiorentini C; Tiberio GAM; Scatolini M; Grosso E; Hantel C; Memo M; Berruti A; Sigala S
    Endocrinology; 2022 Feb; 163(2):. PubMed ID: 34875044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.